Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer Recurrent
Interventions: DRUG: Palbociclib 125mg|DRUG: Standard endocrine therapy
Sponsor: ETOP IBCSG Partners Foundation
Collaborators: Pfizer